within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EL02_Acalabrutinib;
model Acalabrutinib 
   extends Pharmacolibrary.Drugs.ATC.L.L01EL02;

  annotation(Documentation(
    info ="<html><body><p>Acalabrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor used for the treatment of B-cell malignancies, including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). It is approved for use in several countries including the USA and EU.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult patients with B-cell malignancies after oral administration under fasting conditions.</p><h4>References</h4><ol><li><p>Barf, T, et al., &amp; Kaptein, A (2017). Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile. <i>The Journal of pharmacology and experimental therapeutics</i> 363(2) 240–252. DOI:<a href=&quot;https://doi.org/10.1124/jpet.117.242909&quot;>10.1124/jpet.117.242909</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28882879/&quot;>https://pubmed.ncbi.nlm.nih.gov/28882879</a></p></li><li><p>Xu, Y, et al., &amp; Ware, JA (2022). Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment. <i>Journal of clinical pharmacology</i> 62(6) 812–822. DOI:<a href=&quot;https://doi.org/10.1002/jcph.2013&quot;>10.1002/jcph.2013</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34897701/&quot;>https://pubmed.ncbi.nlm.nih.gov/34897701</a></p></li><li><p>Roschewski, M, et al., &amp; Flinn, I (2023). Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment. <i>Clinical cancer research : an official journal of the American Association for Cancer Research</i> 29(17) 3301–3312. DOI:<a href=&quot;https://doi.org/10.1158/1078-0432.CCR-22-2483&quot;>10.1158/1078-0432.CCR-22-2483</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37364001/&quot;>https://pubmed.ncbi.nlm.nih.gov/37364001</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Acalabrutinib;
